Price (delayed)
$14.66
Market cap
$96.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.48
Enterprise value
$50.66M
Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and
There are no recent dividends present for FBRX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.